SPX4,073.44-6.67 -0.16%
DIA343.08-3.07 -0.89%
IXIC11,465.60-2.40 -0.02%

BTIG Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $10

Benzinga · 11/16/2022 08:26
BTIG analyst Justin Zelin maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target from $21 to $10.